171 related articles for article (PubMed ID: 38074659)
1. Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study.
Gao Y; Lu H; Xiong Z
Front Oncol; 2023; 13():1231359. PubMed ID: 38074659
[TBL] [Abstract][Full Text] [Related]
2. The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC.
Sun T; Ren Y; Sun B; Chen L; Zhu L; Zhang L; Zheng C
J Hepatocell Carcinoma; 2023; 10():447-457. PubMed ID: 36960308
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
Cardiovasc Intervent Radiol; 2024 Apr; ():. PubMed ID: 38671322
[TBL] [Abstract][Full Text] [Related]
4. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
5. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
[TBL] [Abstract][Full Text] [Related]
6. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
Huang JT; Zhong BY; Jiang N; Li WC; Zhang S; Yin Y; Yang J; Shen J; Wang WS; Zhu XL
J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study.
Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
Hepatol Res; 2022 Sep; 52(9):794-803. PubMed ID: 35698267
[TBL] [Abstract][Full Text] [Related]
11. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
12. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
Zheng L; Fang S; Wu F; Chen W; Chen M; Weng Q; Wu X; Song J; Zhao Z; Ji J
Front Mol Biosci; 2020; 7():609322. PubMed ID: 33521054
[No Abstract] [Full Text] [Related]
14. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance.
Shi Q; Zhou X; Zhang Z; Zhang W; Ma J; Yang M; Yu J; Luo J; Liu L; Yan Z
Front Immunol; 2022; 13():1097625. PubMed ID: 36703965
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.
Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ; Cheng Y
J Gastrointest Cancer; 2024 Mar; ():. PubMed ID: 38470522
[TBL] [Abstract][Full Text] [Related]
16. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Moriguchi M; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Ogasawara S; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y
Liver Cancer; 2022 Jul; 11(4):354-367. PubMed ID: 35978604
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
[TBL] [Abstract][Full Text] [Related]
18. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
Sheng Y; Wang Q; Liu H; Wang Q; Chen W; Xing W
Br J Radiol; 2024 Feb; 97(1155):668-679. PubMed ID: 38303541
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
